While not CLL specific, there shouldn't be any surprises here. However it is still worth repeating in an unlocked post for anyone with CLL looking for guidance.
A collaborative team of cancer experts from leading academic institutions and organizations has released recommendations for optimal protection against COVID-19 among individuals with blood cancer.
:
A literature review of 24 series showed patients with hematologic malignancies have suboptimal responses to COVID-19 vaccination and boosters.
Lee Greenberger, PhD
Lee Greenberger
“The recommendations were made now because many [patients with blood cancer] take immunosuppressive drugs and are eligible for booster vaccination,” Lee Greenberger, PhD, chief scientific officer of The Leukemia and Lymphoma Society (LLS), said in an interview with Healio. “However, as described in our recently published paper, it is likely that approximately 50% of the patients with hematologic malignancies who did not make anti-spike antibodies to the initial vaccination will make antibodies after booster vaccination. We believe it is critically important for these [patients with blood cancer] to be aware that they still may be vulnerable to COVID-19 infections more so than the general population.”
Awareness and vigilance
In response to the elevated risk patients with blood cancer continue to face, the group of experts recommended the following:
- priority administration of additional vaccine doses to patients with blood cancer;
- ongoing compliance with masking and social-distancing protocols;
- frequent COVID testing, even among those vaccinated, and prompt treatment with monoclonal antibodies, convalescent plasma and antiviral therapies for infected individuals;
- vaccination of those in frequent proximity to individuals with blood cancer, including caregivers and household members aged 12 years and older;
- required COVID-19 vaccination for all health care system staff, and a call to provide staff with priority vaccine administration to maintain high levels of protection in this group; and
- increased awareness of the entire immune response to vaccination in patients with blood cancer, including a better understanding of the correlation between the level of antibodies after vaccination and possible breakthrough infections in such patients.
healio.com/news/hematology-...
In other news:-
USA COVID-19 vaccines' approvals, authorizations, efficacy rates, and dosages
secure.medicalletter.org/do...
FDA Moderna booster vote questions
mdedge.com/hematology-oncol...
Neil